/Investor DB

Apollo Health Ventures — 2021 Investments

4 investments dated 2021 · listed companies and verified rows first · show all

Haya Therapeuticshayatx.comin𝕏Seed · May 2021 · $20M✓ verified

HAYA Therapeutics develops precision RNA medicines that target long non-coding RNAs (lncRNAs) in the regulatory genome to reprogram disease at the level of cell state, with a lead program in cardiac fibrosis and work in obesity and metabolic disease.

AI & Machine LearningBiotechDeep TechHealthtech

Samir Ounzain(Chief Executive Officer (CEO) & Co-founder)inDaniel Blessing(Chief Scientific Officer (CSO) & Co-founder)inRichard Law(Chief Business Officer (CBO))inEric Adam(Chief Operating Officer (COO))inJordan Shin(Chief Medical Officer (CMO))inJérôme Andries(Chief Financial Officer (CFO))in

Co-investorsBroadview VenturesSofinnova Partners+ND Capital4see VenturesLifelinkHumboldt

Abalos Therapeuticsabalos-tx.cominSeries A · Oct 2021 · $36M

Abalos Therapeutics develops immunotherapy treatments using arenavirus-based approaches for cancer.

BiotechHealthtech

Co-investorsVentura BioMed InvestorsBoehringer Ingelheim Venture Fund

Bloom Sciencebloomscience.comin𝕏Dec 2021

Bloom Science is a clinical-stage biotech company developing live biotherapeutic products that replicate the effects of the ketogenic diet through the gut-brain axis.

BiotechDeep TechDigital HealthSan Diego, US

Co-investorsALS Investment FundJoyance PartnersPsyMed VenturesSocial StartsLeaps by Bayer

Ochre Bioochre-bio.comin𝕏Seed · Jun 2021 · $10M

Ochre Bio develops RNA therapeutics and drug discovery platforms targeting liver disease, combining proprietary human liver datasets with AI-driven causal prediction and human tissue validation models.

AI & Machine LearningBiotechHealthtechMedical DevicesLondon, GB

Quin Wills(Founder/CSO)inJack O'Meara(Founder)in

BoardChinwe UkomaduElaine SullivanEliot ForsterJack Castle

Co-investorsBackedBeast VenturesCoastCapEntrepreneur FirstExpaGaingels+18 more

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.